聖諾醫藥-B(02257.HK):Sirnaomics與Sagesse Bio簽署專利轉讓及許可協議
格隆匯8月1日丨聖諾醫藥-B(02257.HK)發佈公吿,2024年8月1日(交易時段前),董事會批准公司的全資附屬公司美國Sirnaomics與Sagesse Bio簽署專利轉讓及許可協議,內容包括(i)向Sagesse Bio轉讓美國Sirnaomics該轉讓專利的權益;(ii)向Sagesse Bio授出美國Sirnaomics於使用領域內之許可專利項下的獨家全球權利及許可;及(iii)向Sagesse Bio披露美國Sirnaomics的專有技術。作為上述專利轉讓及許可的代價,(i)Sagesse Bio與美國Sirnaomics應訂立認購安排;及(ii)達成若干條件後, Sagesse Bio應向美國Sirnaomics支付不超過3300萬美元的里程碑付款。
2024年8月1日(交易時段前),作為專利轉讓及許可協議項下的部分代價,董事會批准美國Sirnaomics (i)與Sagesse Bio籤立認購協議;及(ii)與Sagesse Bio及其他Sagesse股東籤立股東協議(統稱“認購安排”),據此,Sagesse Bio應向美國Sirnaomics發行240萬股Sagesse Bio無表決權股份,佔相關方認購Sagesse Bio股份後Sagesse Bio已發行及流通股本的60%大多數股權,即400萬股股份,每股面值為0.00001美元,分別由美國Sirnaomics、Gore Range(通過Gore Range Fund)及其他Sagesse股東實益擁有60%、20%及20%。相關方認購Sagesse Bio股份後,Sagesse Bio的財務業績、資產及負債將不會併入集團賬目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.